Ratings summary and target price
The majority of analysts providing recommendations for Herbalife (HLF) are maintaining a “neutral” outlook. But given the company’s weak sales and EPS (earnings per share) performance, there could be some downward revisions in the target price. Herbalife reported a YoY (year-over-year) fall in its top-line and bottom-line results in 3Q17. Continued challenges in several regions, including the United States (SPY), Mexico, Central America, and China, are projected to result in lower sales. Input cost pressure stemming from adverse currency movements could hurt the company’s profitability.
The company’s top line is estimated to fall in 2017, driven by lower volume points. However, favorable currency rates are expected to supplement its sales in 4Q17.
About 60.0% of the analysts covering HLF stock recommended a “hold,” and 40.0% maintained a “buy” rating. Analysts are suggesting a target price of $83.75 per share for HLF stock, which reflects an upside of 18.8% to its closing price of $70.47 on November 2, 2017.
About 50.0% of analysts covering Nu Skin Enterprises (NUS) stock are recommending a “buy,” 17.0% are recommending a “hold,” and 33.0% are recommending a “sell.” About 11.0% of the analysts covering Vitamin Shoppe (VSI) have recommended a “buy” for the stock, 67.0% have rated it a “hold,” and 22.0% have rated it a “sell.”